From EU Project to Standard Practice: Sustaining RoIPD Adoption

Every year, hundreds of thousands of people across Europe enrol in clinical trials. They give blood, answer questionnaires, submit to tests, and in some cases take investigational treatments. Their data drives some of the most consequential decisions in medicine.

Almost none of them receive that data back in any meaningful way.

This is not a deliberate policy choice. It is a structural gap, produced by the intersection of legal complexity, fragmented technology systems, and the absence of any standardised process for proactive data return. The EU’s General Data Protection Regulation gives trial participants the right to access their personal data. In practice, exercising that right requires a formal request, knowledge that the right exists, and the ability to interpret data that is typically returned in raw clinical formats without supporting context.

The FACILITATE project, which concluded with its final conference in Modena on 4-5 June 2026 after four years of work under the Innovative Medicines Initiative 2, was built to close that gap.

PRIVANOVA’s Role in the Project

FACILITATE brought together 27 organisations across Europe: universities, hospital networks, patient organisations, pharmaceutical companies, and technology providers, all working within a consortium coordinated by the University of Modena and Reggio Emilia (UNIMORE).

PRIVANOVA played a key role in the project as a co-lead of WP7 (along with GSK), carrying the accountability for business exploitation and sustainability. This is the dimension of research projects that most often fails: four years of rigorous work producing outputs that have no structured path to adoption once project funding ends. WP7 existed precisely to prevent that outcome. It required translating the consortium’s legal, ethical, and technical work into a framework that organisations could actually use, building an adoption model that outlasts the project itself.

That work drew directly on PRIVANOVA’s core professional expertise: understanding how organisations make compliance and implementation decisions, where adoption barriers arise, and how to structure outputs to make the distance between reading a framework and deploying it as short as possible.

What the Project Produced

FACILITATE’s approach rested on a clear principle: build for the real clinical trial environment, not the ideal one. That means resource-constrained sites, multi-country regulatory variation, legacy technology systems, and sponsors under significant time and cost pressure. Every output was designed with these realities in mind.

To make the work accessible across the full range of stakeholders involved in a clinical trial, outputs were organised into five use cases. These address distinct dimensions of what makes the return of individual participant data difficult in practice: participant communication; technical architecture and interoperability; legal and ethical governance; training and education; and operational validation through the project’s dry-run programme. The structure was deliberate. A sponsor’s legal team has different requirements from a clinical site coordinator or a patient organisation. Organising work into distinct, navigable domains means any stakeholder in the clinical trial lifecycle can find what is relevant to their role and act on it directly.

Testing It Against Reality

The dry-run programme deserves particular attention. Rather than validating components individually, it applied the combined outputs of the project to a real clinical study workflow and asked a specific question: what actually happens when a sponsor tries to implement RoIPD in a live trial?

The finding was unambiguous. RoIPD is operationally feasible. It requires early integration into trial design, not late-stage addition. Decisions about data scope, consent architecture, and participant communication format cannot be deferred without compounding cost and complexity downstream. The dry-run report provides sponsors, site teams, legal functions, and patient organisations with a lifecycle-phase analysis, identified gaps, and practical recommendations drawn from that real-world test.

Where the Outputs Live

A significant body of FACILITATE outputs is already publicly available on the project website at facilitate-project.eu. This includes webinar recordings, stakeholder roundtable materials, newsletters, published papers, and training resources developed across the project’s four years. The project’s White Paper, which sets out the framework for returning patient data from clinical trials and received endorsement from industry partners in early 2026, is also accessible there.

Further outputs will be released as they are reviewed and approved through the applicable EU Commission processes. PRIVANOVA will communicate new releases as they become available.

Making the Work Last

The resources FACILITATE produced are freely available for any organisation in the clinical trial lifecycle to use directly or adapt to their own context. Beyond individual use, the frameworks, technical standards, and governance tools are designed to feed into broader EU health data infrastructure, including the European Health Data Space and evolving EMA expectations under the Clinical Trials Regulation.